Bloomia Holdings reported financial results for its first fiscal quarter ended September 30, 2026, with revenue of $5.0 million and a net loss of $2.4 million. Management highlighted a 17% improvement in net loss and a 21% improvement in Adjusted EBITDA compared to the prior year, driven by operational process improvements and lower bulb prices.
Term
Q1 2027
“Our revenue remained stable during the quarter, while we continued to make meaningful progress on the key operational and financial initiatives that are strengthening Bloomia's foundation for long-term growth. This progress is evident in our quarter’s results, where we improved our net loss by 17% and our adjusted EBITDA by 21% over the comparable prior year quarter. Further, we used significantly less cash in the quarter as Dutch bulb prices dropped materially year-over-year. This both strengthens our balance sheet by preserving cash, and leads to improved operating margins for the year ahead.”
Mark Jundt, Chairman and Co-Chief Executive Officer
“Our first fiscal quarter is where we lay the foundation for a successful year. We have dug deep into analyzing our core operating processes, resulting in many process improvements that are simultaneously increasing quality and decreasing waste. We are set up for a year of growth in terms of both revenue and profitability.”
SpyGlass Pharma reported a net loss of $57.9 million for the nine months ended September 30, 2026, compared to $27.3 million in the prior year, driven by increased R&D and G&A expenses. The company significantly strengthened its balance sheet through an initial public offering and the conversion of preferred stock, ending the period with $208.7 million in cash and cash equivalents.
Incannex Healthcare Inc. reported a net loss from operations of $3.44 million for the quarter ended September 30, 2026, an improvement from a $6.79 million loss in the prior year period, primarily due to reduced general and administrative expenses. The company maintained a strong cash position of $68.27 million and continues to focus on its clinical development pipeline, including drug candidates IHL-42X and IHL-675A.
SpyGlass Pharma reported Q3 2026 financial results, highlighting a cash position of $215.8 million which is expected to fund operations through 2028. The company also announced the $13 million acquisition of Advanced Vision Science to secure IOL manufacturing capacity and reported positive four-year follow-up data from its first-in-human study of the BIM-IOL System.
Term
Q3 2026
“SpyGlass Pharma continued to execute our objectives over the course of the quarter as we aim to alter the treatment paradigm for glaucoma patients. Our underlying sustained drug delivery platform delivered four years of safety and efficacy results in the FIH trial of the BIM-IOL System, demonstrating that it can control IOP with unprecedented durability.”
Patrick Mooney, chief executive officer of SpyGlass Pharma
Ondas reported record Q3 2026 revenue of $167.5 million, representing a 100% sequential increase and a 16-fold increase year-over-year. The company raised its full-year 2026 revenue target to at least $550 million and initiated a 2027 revenue target of at least $1.1 billion, driven by strong bookings and backlog growth.
“This quarter demonstrates the growing benefits of Ondas’ integrated operating platform. Our businesses are gaining access to larger customers, broader channels, and stronger production and field-support capabilities, allowing mission-ready technologies to move more quickly from evaluation into deployment.”
Eric Brock, Chairman and CEO of Ondas
“We expect a strong finish to 2026, with momentum accelerating in the fourth quarter as volume deliveries ramp across existing programs and we convert pipeline opportunities into customer programs.”
CorMedix Inc. reported net income of $49.9 million for the nine months ended September 30, 2026, a decrease from $149.0 million in the prior year period, primarily due to higher operating expenses and a significant tax benefit recorded in 2025. Total revenue and grant income grew to $283.9 million for the nine-month period, driven by product sales and new grant income.
Corvex, Inc. reported third quarter 2026 financial results, its first full period following the divestiture of legacy healthcare assets. The company reported revenue of $5.0 million and a net loss of $17.5 million as it transitions to an AI computing platform model.
Term
Q3 2026
“We are building the Corvex AI Factory business one underwritten project at a time, and the third quarter moved that business forward. We have now secured all of the approximately 8 MW of critical IT capacity in the plan we set out in August.”
Jay Crystal, Co-Founder and Co-Chief Executive Officer
“Corvex is an engineering company first. In the third quarter we launched Corvex Token Factory on schedule and received notices of allowance for two patents covering Corvex’s technology, bringing our portfolio to two allowed patents and 10 pending patent applications.”
Seth Demsey, Co-Founder and Co-Chief Executive Officer
Leatt Corporation reported its highest quarterly revenues in four years, with Q3 2026 revenue increasing 43% to $20.46 million. Net income surged 309% to $2.20 million, driven by broad-based growth across body armor and helmet categories and the recoupment of global trade tariffs.
Term
Q3 2026
“The third quarter of 2026 was a strong quarter by nearly every measure. Total global revenues of $20.46 million were our highest in four years, up 43% over the third quarter of 2025.”
Sean Macdonald, Chief Executive Officer
“Net income for the third quarter increased by 309% to $2.20 million as compared to the third quarter of 2025. Gross profit increased by 48% to $9.32 million, in part due to the recoupment of global trade tariffs levied on the importation of goods into the U.S.”
Leatt Corp reported strong growth for the third quarter of 2026, with revenues increasing 43% to $20.46 million and net income rising to $2.20 million compared to $0.54 million in the prior year period. For the nine months ended September 30, 2026, the company generated $4.59 million in net cash from operating activities and maintained a solid balance sheet with $15.43 million in cash and cash equivalents.
RUM Group reported record Q3 2026 revenue of $96.6 million, a 290% year-over-year increase driven by the first full quarter of Quake AI contributions. The company achieved its first-ever profitable quarter on an Adjusted EBITDA basis, supported by high utilization of its 22,000 NVIDIA GPU fleet.
Term
Q3 2026
“Q3 was a defining quarter for RUM Group. We delivered record revenue, nearly four times last year’s, and achieved positive Adjusted EBITDA for the first time in our history. Quake AI is now the engine of our business. We have real assets running real AI workloads for real customers and generating real cash. Our 22,000-GPU estate is nearly sold out at 85% utilization. As capital becomes more selective, we believe it will flow to experienced operators with disciplined balance sheets. That is exactly where RUM Group stands, and we intend to use that position to build lasting value for our shareholders.”
Theriva Biologics reported a net loss of $6.7 million for the nine months ended September 30, 2026, a significant improvement from the $21.7 million loss in the prior year period. The company generated $0.3 million in license revenue and substantially reduced operating expenses, while maintaining a cash balance of $8.5 million as of the end of the quarter.
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled antifibrotic therapies for pulmonary fibrosis, specifically lead candidates AP01 and AP02. As of November 10, 2026, the company reported 44,521,494 shares of voting common stock outstanding and continues to incur significant operating losses to fund its research and development programs.
SeaStar Medical reported a net loss of $11.8 million for the nine months ended September 30, 2026, compared to $9.2 million in the prior year period, driven by increased research and development expenses. Total revenue grew to $1.7 million from $0.8 million year-over-year, while cash reserves decreased significantly to $4.0 million from $12.0 million at the start of the year.
SES AI Corp reported its Q3 2026 financial results, highlighting a 31% sequential revenue increase to $6.6 million and a narrowing GAAP net loss of $13.4 million. The company successfully ramped its Chungju production line to 1 million cells per year and introduced its 'Flywheel' strategy focusing on drones, energy storage, and material discovery.
Suburban Propane Partners reported fiscal year 2026 net income of $109.0 million and Adjusted EBITDA of $284.0 million, a 2.2% increase over the prior year. The company highlighted strong heat-related demand in its propane segment and a 13% increase in average daily renewable natural gas (RNG) injections following facility upgrades and new capacity in New York.
Term
FY2026
“Fiscal 2026 was another strong year for Suburban Propane with solid results in our propane operations, the completion of capital projects to increase the scale of our renewable natural gas (“RNG”) business, and continued debt reduction to further strengthen our financial position.”
Michael A. Stivala, President and Chief Executive Officer
“With these investments in place, we enter fiscal 2027 with a larger, more reliable RNG platform, opportunities to increase production through capacity optimization and higher feedstock intake, and the ability to enhance our earnings profile from the recognition of additional PTCs.”
Michael A. Stivala, President and Chief Executive Officer
MeiraGTx reported a significant increase in total revenue to $326.5 million for the nine months ended September 30, 2026, primarily driven by license and service revenue from related parties. This resulted in a net income of $63.1 million for the period, compared to a net loss of $129.3 million in the prior year, despite a net loss in the third quarter of 2026.
The Dixie Group reported its third consecutive profitable quarter, with net sales increasing 4.6% to $65.2 million and net income of $577,000 compared to a significant loss in the prior year. The company attributed the improvement to cost reductions and operating efficiencies despite industry headwinds from high interest rates and inflation.
Term
Q3 2026
“We are pleased to report our third consecutive profitable quarter of 2026. Net sales increased 4.6% over the third quarter of last year, and we returned to operating income for the quarter compared to an operating loss in the prior year period. Gross profit margins improved to 26.6% from 24.8%, reflecting cost reductions and improved operating efficiencies in our operations.”
Daniel K. Frierson, Chairman and Chief Executive Officer
Forum Markets reported Q3 2026 revenue of $2.0 million and net income of $7.9 million, which included a $13.9 million non-cash gain from digital asset fair value changes. The company highlighted the formation of its Forum Edge AI joint venture and the acquisition of two additional commercial aircraft engines during the quarter.
Term
Q3 2026
“Over the past three months, we established our AI infrastructure platform through our Forum Edge AI joint venture and made it the primary focus of our capital and our growth. We have established the foundation for what we believe can become a substantial AI infrastructure business.”
McAndrew Rudisill, chairman and chief executive officer of Forum Markets
“The midterm elections significantly disrupted an already tightening AI compute market, accelerating rising costs for equipment, compute and financing. These conditions increase the value of data center capacity that is already permitted, powered and built, which is exactly what Forum has.”
McAndrew Rudisill, chairman and chief executive officer of Forum Markets
Lucid Diagnostics reported a net loss of $6.7 million for the quarter ended September 30, 2026, an improvement from the $10.4 million loss in the prior year period. Total revenue remained flat year-over-year at $1.2 million, while the company significantly reduced its total liabilities from $29.5 million at year-end 2025 to $21.9 million.
Theriva Biologics reported third quarter 2026 financial results, highlighting a cash position of $8.5 million and a runway into Q1 2027. The company also noted the completion of the sale of its SYN-004 portfolio to Biossil Labs for $350,000 upfront and up to $91 million in milestones.
“We are pleased with the clinical progress achieved this quarter. Patient enrollment and dosing in the VIRAGE2 trial is progressing well, and we anticipate completing enrollment by the end of the fourth quarter of this year.”
Steven A. Shallcross, Chief Executive Officer of Theriva Biologics
“The recently signed asset sale agreement for SYN-004 (ribaxamase) and the related portfolio of antibiotic-degrading enzymes to Biossil Labs Inc. demonstrates our commitment to deriving value from our legacy microbiome programs while continuing to focus on the development of our lead program VCN-01.”
Steven A. Shallcross, Chief Executive Officer of Theriva Biologics
enCore Energy reported Q3 2026 revenue of $16.7 million, an 88% increase year-over-year driven by higher uranium delivery volumes and stronger realized prices. The company reported a net loss of $33.9 million for the quarter as it focused on wellfield development at Alta Mesa and Upper Spring Creek while implementing cost-reduction measures.
Term
Q3 2026
“2026 has been a challenging year for enCore, and we have responded by reducing costs and focusing our capital where it matters most. We optimized operations to align spending with permitting timelines, while continuing to build the wellfields and infrastructure that underpin our next phase of extraction.”
Aktis Oncology reported a net loss of $72.4 million for the nine months ended September 30, 2026, compared to $48.6 million in the prior year, driven by increased R&D and G&A expenses. The company significantly strengthened its balance sheet during the period through an initial public offering and the conversion of preferred stock, ending the quarter with $492.9 million in cash and marketable securities.
Avalyn Pharma reported financial results for the third quarter of 2026, ending the period with $386.6 million in cash and a runway projected into 2029. The company highlighted clinical progress, including the initiation of a Phase 1 study for its AP03 combination therapy and upcoming Phase 2 data readouts for AP01 and AP02 expected in 2027.
Term
Q3 2026
“As we approach year end, I’m proud of the progress we’ve made across our portfolio and the strong foundation we’ve built for what we expect to be a transformational 2027, with data anticipated across all three of our programs.”
Lyn Baranowski, Chief Executive Officer of Avalyn
“We remain confident in the potential of inhaled therapies to transform the standard of care for pulmonary fibrosis by delivering effective, well-tolerated treatments both as monotherapies and in combination.”
MeiraGTx reported third quarter 2026 financial results and provided a regulatory update for its lead candidate bota-vec, with an MAA submission to the EMA expected in December 2026 and a BLA submission to the FDA in Q1 2027. The company is preparing for a potential commercial launch of bota-vec for XLRP in late 2027 while advancing its Phase 2 AQUAx2 study for radiation-induced xerostomia.
“We are pleased to report that we have now completed much of the work towards submission of full global regulatory filings with the EMA and FDA for bota-vec for the treatment of XLRP. The MAA dossier is complete and awaiting submission and the BLA is expected to follow early next year.”
Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx
“We are actively preparing for our pivotal Phase 2 AQUAx2 12-month data readout for the treatment of radiation-induced xerostomia in mid-2027. As we progress these two lead programs through filing for potential approval and commercialization, we are also advancing several programs towards IND.”
Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx
LiqTech International reported revenue of $12.9 million for the nine months ended September 30, 2026, a slight decrease from $13.4 million in the prior year period. The company significantly strengthened its balance sheet, increasing cash to $13.9 million and total stockholders' equity to $24.3 million, primarily through the issuance of common stock and the settlement of notes payable.
Creatd, Inc. reported a significant increase in net loss for the nine months ended September 30, 2026, reaching $20.2 million compared to $5.1 million in the prior year, primarily driven by a surge in stock-based compensation and general administrative expenses. Net revenue declined by approximately 27% year-over-year to $603,722, while the company's total stockholders' equity decreased to $7.97 million.
Lucid Diagnostics reported third quarter 2026 financial results, highlighting the commencement of Medicare reimbursement for its EsoGuard Esophageal DNA Test at a rate of $1,938.01 per test. The company performed 2,871 tests during the quarter and reported record monthly test volume in October following the Medicare coverage milestone.
“Medicare is now paying for EsoGuard. For the first time, Medicare beneficiaries nationwide have fully reimbursed access to this groundbreaking test. This breakthrough represents a seminal moment in our mission to end the scourge of esophageal cancer and marks the start of a new phase for Lucid focused on commercial acceleration and revenue growth.”
Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer
“Our pursuit of EsoGuard’s enormous clinical and commercial opportunity is now substantially less constrained by external factors. Lucid’s near-term growth now depends almost entirely on our team’s commercial and operational execution. Just a few weeks into this new chapter, our team delivered record monthly test volume in October and is approaching this opportunity with the urgency and determination it deserves. We are laser-focused on expanding access to EsoGuard for Medicare beneficiaries and translating this early momentum into revenue growth. What has been a marathon is now a sprint.”
Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer
Aktis Oncology reported financial results for the third quarter of 2026, highlighting the initiation of its third Phase 1b clinical trial (BActinium-2) for AKY-2519. The company also operationalized its in-house GMP manufacturing facility in Boston and remains on track to present preliminary clinical data for its lead programs in 2027.
Term
Q3 2026
“Aktis is on a trajectory to redefine radiopharmaceuticals as a major pillar of cancer treatment by expanding the modality to more targets, broader indications, and larger patient populations. In the third quarter, we continued to make tremendous progress operationalizing this vision.”
Matthew Roden, Ph.D., President and Chief Executive Officer
“With the initiation of the BActinium-2 trial of AKY-2519, we now have three clinical trials underway in the U.S. across two novel targets, Nectin-4 and B7-H3, which are both implicated in a range of solid tumor types. We also opened the first backfill cohorts in our ongoing NECTINIUM-2 and BActinium-1 trials to further characterize safety and preliminary antitumor activity at the selected doses, while dose escalation continues in both studies.”
Matthew Roden, Ph.D., President and Chief Executive Officer
Kyverna Therapeutics reported a net loss of $119.99 million for the nine months ended September 30, 2026, compared to $123.50 million in the prior year period. The company's cash and marketable securities position decreased to $170.57 million as of September 30, 2026, down from $279.25 million at the end of 2025, primarily due to ongoing research and development expenses.
Cohen & Co Inc. reported third quarter 2026 financial results, generating $32.4 million in total revenue and $6.9 million in enterprise net income. The company's capital markets division underwrote six SPAC IPOs during the quarter, though results were impacted by $17 million in mark-to-market adjustments. Additionally, the board declared a quarterly dividend of $0.25 per share and appointed Daniel G. Cohen as CEO.
Term
3 years
“We are encouraged by the continued strong performance in our full-service boutique investment bank, Cohen & Company Capital Markets (“CCM”), and in our gestation repo business. During the third quarter, CCM underwrote six SPAC IPOs and one closed-end fund, raising $1.8 billion for clients, and advised on and raised capital for eight de-SPAC transactions, exemplifying its status as a leading SPAC advisor on Wall Street.”
Daniel G. Cohen, Executive Chairman and Chief Executive Officer
“While third quarter results were unfavorably impacted by more than $17 million of mark-to-market adjustments in our investment banking and new issue revenue line, in large part due to the environment in our businesses, we still generated $6.9 million of enterprise net income and $648,000 of adjusted pre-tax income.”
Daniel G. Cohen, Executive Chairman and Chief Executive Officer